37 results about "Anti-Rabies virus IgG" patented technology

The present invention provides pharmaceutical antibody formulations, in particular liquid pharmaceutical formulations comprising anti-rabies virus antibodies. The formulations can be used in the post exposure prophylaxis of rabies.

A novel chimeric protein of rabies virus designed to express a chimeric G protein at a high level in transgenic plants. A gene was also designed and chemically synthesised to encode the chimeric G protein and expressed at high level in plant tissue. The gene was expressed in transgenic tobacco plants to examine its therapeutic efficacy against infection by rabies virus. The chimeric G protein was enriched in plant membranes. The BalbC mice were immunised with the plant leaf expressed G-protein. Plant derived chimeric G protein elicited higher immune response as compared to the commercial vaccine. The mice displayed protective immunity when they were challenged with live virus. Chimeric G protein expressed at high level in plant leaves was demonstrated to function as a commercially valuable subunit vaccine against rabies virus infection.

The present invention provides vectors that contain and co-express in vivo or in vitro immunogenic polypeptides or antigens together with an OX40L polypeptide, which functions as a genetic adjuvant. Together, the immunogenic polypeptide and the OX40L polypeptide elicit an immune response in animal or human, which is greater than the immune response elicited by the immunogenic polypeptide alone. In a particular example, the invention provides vectors encoding a Rabies G immunogenic polypeptide and a canine OX40L genetic adjuvant, which vectors elicit strong immune responses in canine against rabies virus.

The invention relates to a human anti-rabies virus IgG antibody ELISA test kit. An ELISA plate is firstly coated with an anti-rabies virus monoclonal antibody, wherein the coating buffer solution is a 0.05M carbonate buffer solution of which the pH value is 9.6, and the coating amount is 0.1-1ug per hole; a blocking solution is a BSA or skimmed milk of which the mass concentration is 1-10%; the ELISA plate is coated with a rabies virus purified antigen after being blocked, wherein the coating amount is 0.1-1ug per hole; a sample diluent is a 0.01mol / L phosphate buffer solution (PBS) which contains bovine serum albumin (BSA) with a mass concentration of 0.1-10% and NaN3 with a mass concentration of 0.01-0.05 and has a pH value of 7.2-7.4; an enzyme conjugate is a horse radish peroxidase-mouse anti-human IgG enzyme conjugate; a concentrated cleaning solution is a 0.01mol / L PBS which contains tween-20 with a volume concentration of 0.05% and has a pH value of 7.2-7.4; a zymolyte A solution is a 3,3'-5,5'-tetramethyl benzidine solution, and a zymolyte B solution is an oxydol solution; and a stop solution is a 1mol / L H2SO4 solution, and a positive control and a negative control are arranged in the kit. The specificity of the kit is up to 100%, and the sensitivity is 1:640. The kit is used for evaluating the immunity effect of humans inoculated with rabies vaccines.

The invention discloses an anti-rabies virus monoclonal antibody and a preparation method and an application, belonging to the field of biomedicine and particularly relating to the preparation of a monoclonal antibody capable of identifying rabies virus and the application. The monoclonal antibody of the invention is screened by indirect Enzyme-linked immunosorbent assay (ELISA), and specificity and affinity thereof combined with antigen are identified by methods such as polyacrylamide gel electrophoresis analysis, speckle ELISA, immunoblot analysis and the like. The anti-rabies virus monoclonal antibody of the invention can be applied in multiple testing methods of antigen of rabies virus and can be also applied in the preparation of rabies virus detecting kit. The anti-rabies virus monoclonal antibody is secreted by anti-rabies virus monoclonal antibody hybridoma cell strain 2C5 with the preservation number being CGMCC No.3014.

The invention aims at providing a rabies virus resistant neutralizing antibody, and particularly provides a humanized or completely humanized monoclonal antibody to meet the requirement for clinically diagnosing and / or treating rabies. A phage antibody library is prepared by adopting a phage antibody library technology and taking 32 parts of high-potency healthy human peripheral blood inoculated with rabies vaccines as a raw material; 7 ELISA positive antibodies are obtained through three rounds of screening from the phage antibody library; and furthermore, the neutralizing activity of the 7 ELISA positive antibodies is measured through an RFFIT method, wherein four ELISA positive antibodies, namely R5, R7, R8 and R9, have higher neutralizing activity in all. The rabies virus resistant neutralizing antibody with high affinity, which is provided by the invention, can be used for substituting ERIG and HRIG to carry out active and / or passive immune therapy on rabies virus seriously-exposed persons.

The invention relates to the technical field of biomedical engineering, and discloses a method for screening and verifying neutralizing antibodies against rabies virus from a phage antibody library, including A, culturing monoclonal phage antibodies, and taking the culture supernatant; B, qualitative analysis : The culture supernatant in step A was placed in a 96-well plate, followed by DMEM medium and neutralizing virus neutralization, BSR cell suspension culture, pre-cooled acetone fixation, and diluted FITC-labeled anti- Co-incubation with rabies virus nucleoprotein antibody, select clones that can significantly inhibit virus infection and sequence them, eliminate repetitive sequences, and initially obtain anti-rabies virus antibody sequences with different neutralizing activities; C. Quantitative analysis: select different sequences with neutralizing activities Each clone of the phage antibody particles was re-prepared, purified and diluted to a certain number of times, and the in vitro neutralization activity was determined by RFFIT method; and D, the transient expression and activity analysis of the whole molecule antibody.